Noticias Arbutus Biopharma Corporation - ABUS | Acciones NASDAQ

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for...

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus”...

Form 8-K - Current report

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus”...

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The...

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus”...

Form 8-K - Current report

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus”...

Form 8-K - Current report

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus”...

db7 3 semanas hace

nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944

2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data

👍️0

mick 2 meses hace

https://www.stockscores.com/charts/charts/?ticker=ABUS

👍️0

mick 3 meses hace

ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT

👍️0

db7 3 meses hace

breaking out; dare i say 'someone' knows 'something'(?)

👍️0

db7 3 meses hace

ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"

Monksdream 3 meses hace

ABUS under $4

👍️0

DewDiligence 4 meses hace

ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.

👍️0

Rockurstocks 4 meses hace

Not for long! $ABUS$

👍️0

Monksdream 4 meses hace

ABUS under $4

👍️0

mick 5 meses hace

ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT

👍️0

Monksdream 5 meses hace

ABUS new 52/week high

https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt

👍️0

db7 6 meses hace

New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852

👍️0

db7 6 meses hace

Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf

👍️0

mick 6 meses hace

ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes

👍️0

db7 6 meses hace

EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"

👍️0

db7 6 meses hace

Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value

👍️0

db7 7 meses hace

issue here, now, might be too many open $3 calls? will mm's hold her under....

👍️0

db7 7 meses hace

mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price

https://www.businesswire.com/news/home/20240517970994/en/

👍️0

db7 7 meses hace

from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."

👍️0

Monksdream 7 meses hace

ABUS under $3

👍️0

mick 7 meses hace

TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:

👍️0

Monksdream 8 meses hace

ABUS new 52 hi

👍️0

db7 8 meses hace

looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june

👍️0

mick 8 meses hace

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

👍️0

mick 8 meses hace

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

👍️0

mick 8 meses hace

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

👍️0

mick 8 meses hace

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

👍️0

mick 8 meses hace

Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

👍️0

mick 8 meses hace

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

👍️0

Paullee 8 meses hace

07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.

👍️0

MWM 8 meses hace

Watching all 3 stocks. $ABUS is kind of moving...

👍️0

db7 8 meses hace

was going to take all '3' to explode imo..

👍️0

MWM 8 meses hace

Yes, I'm trying to read it myself

👍️0

db7 8 meses hace

decision is out; looks like arbutus won '2' and moderna '1' .. please confirm

👍️0

db7 9 meses hace

https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/

👍️ 1

Desert dweller 9 meses hace

My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.

👍️ 1

Desert dweller 10 meses hace

Handle on twitter is @DesertDweller93

👍️0

MWM 10 meses hace

Great post!

What’s your handle on Twitter?

👍️0

Desert dweller 10 meses hace

I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.

👍️0

MWM 10 meses hace

A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s

👍️0

db7 10 meses hace

yes, quite the drop yesterday and today on mrna... g/l!

👍️0

MWM 10 meses hace

Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...

👍️0

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Arbutus Biopharma Corporation (ABUS)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

ABUS Noticias

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Form 8-K - Current report

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arbutus to Present at Jefferies London Healthcare Conference

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Form 8-K - Current report

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Form 8-K - Current report

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

ABUS Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Arbutus Biopharma Corporation (ABUS) Noticias

Arbutus Biopharma Corporation (ABUS)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

ABUS Noticias

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Form 8-K - Current report

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arbutus to Present at Jefferies London Healthcare Conference

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Form 8-K - Current report

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Form 8-K - Current report

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

ABUS Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación